Skip to main content
PAS 2024 Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Pre-Conference Ticketed Event
Pre-Conference Ticketed Event
APA Award Winner
APA Award Winner
APS Award Winner
APS Award Winner
ASPN Award Winner
ASPN Award Winner
SPR Award Winner
SPR Award Winner
On Demand Presentation
On Demand Presentation
Poster Icons
SPR Award Winner
SPR Award Winner
Back
Evaluation ViewAttendees 6

Hematology/Oncology

Session: Hematology/Oncology

The Oncolytic Activity of Zika Viral Therapy Confers a Dramatic Survival Advantage in High-Risk Neuroblastoma In Vivo Models

Saturday, May 4, 2024
11:30 AM – 11:45 AM ET
Location: Metro Toronto Convention Centre: 605
CE Enduring CME: 0.25
Publication Number: 2085.4
Joseph Mazar, Nemours Children's Health, Davenport, FL, United States; Emma Sutton, Nemours Children's Hospital, Orlando, FL, United States; Rosa Rosario, Nemours Children's Hospital, Orlando, FL, United States; Simon P. Cooper, Nemours Children's Hospital, Orlando, FL, United States; Tamarah Westmoreland, Nemours Children's Hospital, Orlando, FL, United States

    Presenting Author(s)

  • Joseph Mazar, PhD (he/him/his)

    Research Scientist/Assistant Professor
    Nemours Children's Health
    Davenport, Florida, United States

    Slides
Disclosure(s):
Joseph Mazar, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Emma Sutton, BS: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Rosa Rosario, BA: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Simon P. Cooper, B.S Microbiology and Cell Science: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Tamarah Westmoreland, MD, PhD: I do not have any relevant financial / non-financial relationships with any proprietary interests.